This prospective cohort and risk score development study determines that risk prediction models for cardiovascular disease using body mass index and lipid levels perform better in people with severe mental illness compared with models that include only established risk factors.
This randomized trial compares the effects of metformin vs placebo on weight gain in children and adolescents with autism spectrum disorder taking atypical antipsychotics.
This case control study suggests that oleoylethanolamide-mediated signaling plays an important role for hedonic regulation of food-craving and obesity in humans and, thus, may be a valuable target for developing novel antiobesity drugs.
This study determines the neural correlates of disturbed body awareness in borderline personality disorder and its associations with emotional dysregulation.
This 38-year longitudinal study of a representative birth cohort (the Dunedin Multidisciplinary Health and Development Study of New Zealand) tests associations between cannabis use over 20 years and a variety of physical health indexes at early midlife.
This prospective cohort study of black and white community-dwelling older adults in the Health, Aging, and Body Composition study investigates the association between trajectories of depressive symptoms and risk of dementia in older adults.
Blumenthal and colleagues estimate weight gain associated with specific antidepressants over the 12 months following initial prescription in a large and diverse clinical population.
This study discusses the association between levels of high-sensitivity C-reactive protein and general psychological distress symptoms.
This pharmacoepidemiology study examines associations between first-trimester antipsychotic exposure and risk for overall congenital and cardiac malformations among children born to women enrolled in Medicaid.
This population-based longitudinal study investigates the association of circulating levels of vitamin B12, folate, and sulfur amino acids with the rate of total brain volume loss and the change in white matter hyperintensity volume in older adults.
This randomized, double-blind, parallel-group, forced-dose titration, placebo-controlled clinical trial demonstrates efficacy for the 50- and 70-mg/d dosages of lisdexamfetamine dimesylate compared with placebo for treatment of binge-eating disorder.